Other Events ·
BioHarvest advances Olive Cell asset to commercial readiness for CDMO licensing
BHSTBioharvest Sciences Inc.
BioHarvest Sciences announced that its proprietary Olive Cell composition has completed development and the self-affirmed GRAS process, reaching commercial readiness. The high-potency Verbascoside ingredient is now available for licensing and manufacturing through the company's CDMO business at its GMP facility. Preliminary in-vitro data showed dose-dependent reductions in lipid accumulation and collagen production in liver models. BioHarvest Sciences Inc. is a biotechnology company pioneering Botanical Synthesis technology to produce plant-derived compounds.